3011 studies found for:
novartis
Create an RSS feed from your search for:
Download the search results for:| Rank | Status | Study | ||||
|---|---|---|---|---|---|---|
| 21 | Completed |
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
|
||||
| 22 | Completed |
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
|
||||
| 23 | Completed |
Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
|
||||
| 24 | Completed |
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
|
||||
| 25 | Completed |
Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers
|
||||
| 26 | Recruiting |
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 11 to 55 Years of Age in the Republic of South Korea
|
||||
| 27 | Recruiting |
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
|
||||
| 28 | Completed |
Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers
|
||||
| 29 | Active, not recruiting |
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
|
||||
| 30 | Recruiting |
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
|
||||
| 31 |
Completed
Has Results |
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea
|
||||
| 32 | Completed |
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
|
||||
| 33 | Completed |
Safety, Tolerability and Immunogenicity of Two Different Formulations of MenB Vaccine, When Administered to Healthy Infants
|
||||
| 34 | Completed |
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
|
||||
| 35 | Completed |
Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults
|
||||
| 36 | Completed |
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
|
||||
| 37 | Completed |
Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine
|
||||
| 38 | Recruiting |
Understanding the Immune Response to Two Different Meningitis Vaccines
|
||||
| 39 | Not yet recruiting |
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older
|
||||
| 40 | Not yet recruiting |
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
|
† Indicates status has not been verified in more than two years